Clinical Trials
1
Active:0
Completed:0
Trial Phases
1 Phases
Phase 1:1
Drug Approvals
0
Drug Approvals
No drug approvals found
This company may not have drug approvals in our database
Clinical Trials
Distribution across different clinical trial phases (1 trials with phase data)• Click on a phase to view related trials
Phase 1
1 (100.0%)Study of SNX281 in Subjects With Advanced Solid Tumors and Lymphoma
Phase 1
Terminated
- Conditions
- Advanced Solid TumorAdvanced Lymphoma
- Interventions
- First Posted Date
- 2020-10-30
- Last Posted Date
- 2024-01-30
- Lead Sponsor
- Stingthera, Inc.
- Target Recruit Count
- 27
- Registration Number
- NCT04609579
- Locations
- 🇺🇸
Sarah Cannon Research Institute at HealthONE, Denver, Colorado, United States
🇺🇸Florida Cancer Specialists, Sarasota, Florida, United States
🇺🇸Thomas Jefferson University, Sidney Kimmel Cancer Center, Philadelphia, Pennsylvania, United States
News
No news found